-

Incretin-based Drugs Market Forecast Report 2025-2034 Featuring AstraZeneca, Boehringer Ingelheim, Eli Lilly and Co, GSK, Lupin, Merck, Novo Nordisk, Pfizer, Sanofi, Takeda, Viatris - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Incretin-based Drugs Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034" report has been added to ResearchAndMarkets.com's offering.

The Incretin-based Drugs Market was valued at USD 37.4 billion in 2024, and is projected to reach USD 68.7 billion by 2034, rising at a CAGR of 6.3%.

The market is categorized by drug type into GLP-1 receptor agonists and DPP-4 inhibitors, with a market size of USD 35.5 billion in 2023. The rising demand for GLP-1 receptor agonists is driven by their ability to enhance insulin secretion and suppress glucagon levels, effectively managing blood sugar. These drugs also promote weight loss by controlling appetite and slowing digestion, making them a preferred option for diabetes patients. Extended-release formulations, such as once-weekly injections, improve patient adherence and expand market reach.

The market is also segmented by the route of administration into oral and injectable drugs. The oral segment accounted for USD 28.7 billion in 2024, with a market share of 76.8%. Oral formulations offer a convenient alternative to injections, leading to higher patient compliance. Continuous research efforts have led to improved efficacy and safety profiles, making oral medications increasingly preferred. These formulations are easy to distribute, store, and administer, reducing the burden on healthcare providers and enhancing accessibility across various healthcare settings.

By indication, the market includes type 2 diabetes mellitus, obesity and weight management, and other metabolic disorders. The type 2 diabetes mellitus segment held the largest share, generating USD 26.6 billion in revenue in 2024. The rising global incidence of type 2 diabetes, attributed to poor dietary habits and lifestyle factors, fuels the demand for incretin-based drugs. These medications effectively lower blood sugar levels while reducing the risk of hypoglycemia, offering a safer treatment option for aging populations and those prone to severe blood sugar fluctuations.

The distribution channel segment comprises hospital pharmacies, retail pharmacies, and e-commerce. Hospital pharmacies led the market with USD 19.2 billion in revenue in 2024. These settings ensure secure access to medications, particularly for newly diagnosed patients or those requiring specialized care. Pharmacists provide guidance on dosage, side effects, and formulation differences, enhancing treatment adherence. Comprehensive support services, including medication management programs and close monitoring of treatment responses, further contribute to market growth.

North America dominated the market, accounting for USD 17.1 billion in 2024, with the U.S. leading at USD 15.5 billion. The rising prevalence of diabetes, cardiovascular diseases, and obesity continues to drive demand for incretin-based drugs. Supportive regulatory frameworks and rapid advancements in drug development contribute to the region's market expansion.

Comprehensive Market Analysis and Forecast

  • Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape
  • Competitive landscape with Porter's Five Forces and PESTEL analysis
  • Market size, segmentation, and regional forecasts
  • In-depth company profiles, business strategies, financial insights, and SWOT analysis

Companies Featured

  • AstraZeneca
  • Boehringer Ingelheim
  • Eli Lilly and Company
  • GlaxoSmithKline
  • Lupin Limited
  • Merck
  • Novo Nordisk
  • Pfizer
  • Sanofi
  • Takeda Pharmaceutical Company
  • Viatris

Key Attributes:

Report Attribute Details
No. of Pages 120
Forecast Period 2024 - 2034
Estimated Market Value (USD) in 2024 $37.4 Billion
Forecasted Market Value (USD) by 2034 $68.7 Billion
Compound Annual Growth Rate 6.3%
Regions Covered Global

Key Topics Covered:

Chapter 1 Methodology and Scope

Chapter 2 Executive Summary

2.1 Industry 360 Synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis

3.2 Industry impact forces

3.2.1 Growth drivers

3.2.1.1 Rising prevalence of type 2 diabetes mellitus

3.2.1.2 Shift toward non-insulin therapies

3.2.1.3 Advancements in drug delivery technologies

3.2.1.4 Cardiovascular and weight management benefits

3.2.2 Industry pitfalls and challenges

3.2.2.1 High treatment costs

3.2.2.2 Adverse effects and contraindications

3.3 Growth potential analysis

3.4 Regulatory landscape

3.5 Gap analysis

3.6 Pipeline analysis

3.7 Porter's analysis

3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

4.1 Introduction

4.2 Company market share analysis

4.3 Competitive analysis of major market players

4.4 Competitive positioning matrix

4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, by Drug Type, 2021-2034 ($ Mn)

5.1 Key trends

5.2 GLP-1 receptor agonists

5.3 DPP-4 inhibitors

Chapter 6 Market Estimates and Forecast, by Route of Administration, 2021-2034 ($ Mn)

6.1 Key trends

6.2 Oral

6.3 Injectable

Chapter 7 Market Estimates and Forecast, by Indication, 2021-2034 ($ Mn)

7.1 Key trends

7.2 Type 2 diabetes mellitus

7.3 Obesity and weight management

7.4 Other metabolic disorders

Chapter 8 Market Estimates and Forecast, by Distribution Channel, 2021-2034 ($ Mn)

8.1 Key trends

8.2 Hospital pharmacies

8.3 Retail pharmacies

8.4 E-commerce

Chapter 9 Market Estimates and Forecast, by Region, 2021-2034 ($ Mn)

9.1 Key trends

9.2 North America

9.2.1 U.S.

9.2.2 Canada

9.3 Europe

9.3.1 Germany

9.3.2 UK

9.3.3 France

9.3.4 Spain

9.3.5 Italy

9.3.6 Netherlands

9.4 Asia-Pacific

9.4.1 China

9.4.2 Japan

9.4.3 India

9.4.4 Australia

9.4.5 South Korea

9.5 Latin America

9.5.1 Brazil

9.5.2 Mexico

9.5.3 Argentina

9.6 Middle East and Africa

9.6.1 South Africa

9.6.2 Saudi Arabia

9.6.3 UAE

Chapter 10 Company Profiles

For more information about this report visit https://www.researchandmarkets.com/r/nygpby

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Research and Markets


Release Versions

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

More News From Research and Markets

Recreational Boat Market Research Report 2025-2030 with Exclusive Data on 33 Vendors Including Leading Players - Azimut-Benetti, BENETEAU, Brunswick, Ferretti, and Yamaha - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Recreational Boat Market Research Report 2025-2030" report has been added to ResearchAndMarkets.com's offering. The Recreational Boat Market was valued at USD 37.40 billion in 2024, and is projected to reach USD 55.20 billion by 2030, rising at a CAGR of 6.70%. The global recreational boat market report consists of exclusive data on 33 vendors. The market is highly concentrated, with many local and international players in the market. The competition among these pl...

Middle East Data Center Colocation Outlook & Forecast Report 2025: A $7.7 Billion Market by 2030 - AI Adoption, Sustainability Mandates, and Smart City Expansion Drive Infrastructure Investments - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Middle East Data Center Colocation Market - Industry Outlook & Forecast 2025-2030" report has been added to ResearchAndMarkets.com's offering. The Middle East Data Center Colocation Market was valued at USD 2.61 billion in 2024, and is projected to reach USD 7.70 billion by 2030, rising at a CAGR of 19.76%. Cumulatively from 2025 to 2030, the Middle East data center colocation market is expected to witness investments of approximately $33.79 billion, of which S...

Automated Blinds and Shades Market - Global Outlook & Forecast 2025-2030 Featuring Key Companies - Hunter Douglas, Lutron Electronics, Legrand, Springs Window Fashions, and Crestron Electronics - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Automated Blinds and Shades Market - Global Outlook & Forecast 2025-2030" report has been added to ResearchAndMarkets.com's offering. The global automated blinds and shades market is expected to reach a value of $5.72 billion by 2030 from $4.02 billion in 2024, growing at a CAGR of 6.08% from 2024 to 2030 Competitiveness in the global automated blinds and shades market arises from smart home features, energy-saving features, and contemporary designs. The top au...
Back to Newsroom